<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969084</url>
  </required_header>
  <id_info>
    <org_study_id>2013P-000057</org_study_id>
    <secondary_id>IIS trial 1218.137</secondary_id>
    <nct_id>NCT01969084</nct_id>
  </id_info>
  <brief_title>The Effect of Linagliptin on Mitochondrial and Endothelial Function</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose to examine the effect of 12 weeks of Linagliptin, a diabetes drug,
      treatment on inflammation as well as vascular and mitochondrial function in diabetic
      patients. Investigators hypothesize that Linagliptin will reduce the proinflammatory state,
      improve endothelial function, increase the blood flow at the muscle microcirculation level
      and improve mitochondrial function. In this study, investigators will perform tests that
      evaluate the function of small and large blood vessels by employing ultrasound and laser
      doppler techniques. In addition MRI scans that evaluate the mitochondrial function of the
      lower extremity muscles at rest and during exercise will also be employed. Forty subjects
      with Type 2 diabetes will be studied for twelve weeks and half of them will be randomly
      assigned to receive linagliptin while the other half will receive placebo. All tests will be
      performed at the beginning and the end of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phosphocreatine (PCR) Recovery Time After Exhaustive or up to 6 Minutes of Leg Exercise.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in the time to phosphocreatine recovery between the baseline visit and post-treatment visit following the graded exercise test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Oxygenation Recovery Time</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in muscle oxygenation after ischemia inducing occlusion for 4 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vascular Reactivity in the Micro- and Macro-circulation.</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in markers of macro- and microvascular function from the baseline visit to the post-treatment visit between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in SDF1-α and Substance P</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Circulating Endothelial Progenitor Cell Phenotypes</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The measurements of the various EPC phenotypes were performed at the Beth Israel Deaconess Flow Cytometry Core Facility. Immunofluorescent cell staining was performed on peripheral blood with the use of the fluorescent conjugated antibodies. 1.000.000 events per sample were acquired using a FACS LSR II analyzer (Becton Dickinson, Franklin Lakes, NJ, USA) and the results were analyzed using the Beckman Coulter Kaluza analysis software (Beckman Coulter Inc., Brea, CA, USA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects given Linagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects given sugar pill/placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <arm_group_label>Linagliptin</arm_group_label>
    <other_name>Tradjenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microcirculation testing</intervention_name>
    <description>The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.</description>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Macrocirculation testing</intervention_name>
    <description>Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).</description>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI Scans</intervention_name>
    <description>Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.</description>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with T2DM whose medical or lifestyle treatment regimen is stable and not
             expected to be changed during the study period. Patients will be considered stable on
             their treatment regimen if there have not been any changes in the type of their
             antidiabetic medications over the past 3 months and/or there have not been any changes
             in their blood glucose levels that have caused them to see their health care provider
             more often than usual over the preceding three months. The diagnosis of T2DM will be
             according to the American Diabetes Association criteria. Subjects previously diagnosed
             with T2DM will not require confirmatory testing.

          -  Age 30-70 years

          -  Patients on insulin should be on a stable insulin regimen for at least 4 months prior
             to enrollment.

          -  Patients on antidiabetic treatment will be eligible if they are stable and no change
             in their treatment is planned for the next three months while they are in the study.

          -  HBA1c ≤ 10.0

        Exclusion Criteria:

          -  Patient with unstable diabetes that has resulted in hyperosmolar coma, DKA, and/or
             documented increase or decrease in HbA1c of more than 2.0% within the previous 6
             months

          -  Treatment with DPP4 Inhibitors or GLP-1 agonists. Patients who discontinued such
             treatment should be at least free for a 3-month period.

          -  Severe proliferative retinopathy that renders the subject legally blinded

          -  Previously intermittent claudication or diagnosed severe peripheral arterial disease
             requiring intervention.

          -  History of Deep Vein Thrombosis (DVT) within the past 3 months.

          -  Significant limb swelling due to lymphedema

          -  Previous diagnosis of severe gastroparesis diabeticorum due to autonomic neuropathy
             that has necessitated hospital admission

          -  Presence of non-healing foot ulceration due to severe peripheral diabetic neuropathy

          -  History of pancreatitis

          -  Documented diabetic nephropathy manifested as macro-albuminuria before enrollment in
             the study, (2 of 3 urine specimens collected within a 3-6 month period with urine
             albumin&gt; 300 ug/mg creatinine - according to the ADA position statement)

          -  Smokers. Smokers will be defined as any subject who reports tobacco use during the
             three months before to study enrollment.

          -  Active or uncontrolled cardiovascular disease as follows:

               1. Myocardial infarction, or angina within 12 months of study participation

               2. Arrhythmia (uncontrolled, highly symptomatic, requires treatment or
                  life-threatening).

               3. Patients with congestive heart failure requiring pharmacologic management,
                  particularly when accompanied by hypoperfusion and hypoxemia due to unstable or
                  acute failure, are at increased risk of lactic acidosis.

               4. Stroke or transient ischemic attack within 12 months of study participation

               5. Uncontrolled hypertension: SBP&gt; 180 mmHg or DBP&gt; 105 mmHg (2 abnormal readings
                  during visit)

          -  Liver disease (AST, ALT Alk Phos levels &gt;2x upper normal limit) at the time of
             enrollment

          -  Renal disease (creatinine &gt; 2 mg/dL and/or estimated GFR &lt;30 mL/min, history of
             dialysis, nephrotic syndrome) at the time of enrollment.

          -  Severe dyslipidemia (triglycerides&gt;600 mg/dL or cholesterol &gt;350 mg/dL) Subjects with
             hypertriglyceridemia may be retested in 2-3 weeks as the values can fluctuate
             tremendously within a few days. In the event that the retested value allows the
             patient to be enrolled, a planned deviation will be submitted to the CCI.

          -  Any other serious chronic disease requiring active treatment.

          -  Pregnancy or Lactation

          -  Females of childbearing potential not using an effective form of birth control as
             determined by the investigators.

          -  Subjects on any of the following medications:

               1. Systemic (not inhaled) Glucocorticoids

               2. Antineoplastic agents

               3. Rifampin

          -  Patient is known to have a history of immunodeficiency diseases, including a positive
             HIV (ELISA and Western blot) and/or positive Hepatitis B surface antigen (HBsAg) or
             Hepatitis C test result in the past.

          -  History of drug or alcohol abuse within the 12 months prior to dosing or evidence of
             such abuse as indicated by the laboratory assays conducted during the screening or
             baseline evaluations.

          -  Acute or chronic metabolic acidosis, including diabetic ketoacidosis.

          -  History of hypersensitivity reaction to linagliptin (such as urticaria, angioedema, or
             bronchial hyperreactivity) or metformin.

          -  Contraindications to MRI: Medically unstable or hematologic, renal, or hepatic
             dysfunction, cardiac pacemaker, Intracranial clips, metal implants, or external clips
             within 10 mm of the head,

          -  Metal in eyes.

          -  Pregnant or nursing women -

          -  Claustrophobia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Baltzis D, Dushay JR, Loader J, Wu J, Greenman RL, Roustit M, Veves A. Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study. J Clin Endocrinol Metab. 2016 Nov;101(11):4205-4213. Epub 2016 Sep 1.</citation>
    <PMID>27583476</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <results_first_submitted>September 20, 2016</results_first_submitted>
  <results_first_submitted_qc>November 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2016</results_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Aristidis Veves</investigator_full_name>
    <investigator_title>Research Director, Microcirculation Lab and Joslin-Beth Israel Deaconess Foot Center</investigator_title>
  </responsible_party>
  <keyword>Type II Diabetes Mellitus</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Linagliptin</keyword>
  <keyword>Tradjenta</keyword>
  <keyword>Glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>45 subjects were enrolled and 41 were randomized to the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Linagliptin</title>
          <description>Subjects given Linagliptin
Linagliptin
Microcirculation testing: The endothelial function of the micro-circulation was assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
Macrocirculation testing: Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodila</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Subjects given sugar pill/placebo
Placebo
Microcirculation testing: The endothelial function of the micro-circulation was assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
Macrocirculation testing: Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasod</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21">One subject withdrew due to unrelated serious adverse event</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Linagliptin</title>
          <description>Subjects given Linagliptin
Linagliptin
Microcirculation testing: The endothelial function of the micro-circulation was assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
Macrocirculation testing: Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodila</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Subjects given sugar pill/placebo
Placebo
Microcirculation testing: The endothelial function of the micro-circulation was assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
Macrocirculation testing: Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasod</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.79" spread="5.75"/>
                    <measurement group_id="B2" value="56.76" spread="6.79"/>
                    <measurement group_id="B3" value="58.67" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phosphocreatine (PCR) Recovery Time After Exhaustive or up to 6 Minutes of Leg Exercise.</title>
        <description>Change in the time to phosphocreatine recovery between the baseline visit and post-treatment visit following the graded exercise test.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Subjects given Linagliptin
Linagliptin
MRI Scans: Phosphorus-31 MRI data was obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Subjects given sugar pill/placebo
Placebo
MRI Scans: Phosphorus-31 MRI data was obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.</description>
          </group>
        </group_list>
        <measure>
          <title>Phosphocreatine (PCR) Recovery Time After Exhaustive or up to 6 Minutes of Leg Exercise.</title>
          <description>Change in the time to phosphocreatine recovery between the baseline visit and post-treatment visit following the graded exercise test.</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-23.3" upper_limit="15.3"/>
                    <measurement group_id="O2" value="1.01" lower_limit="-36.8" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data were expressed as the median (25th:75th percentiles) for non-normally distributed data. The mean±sd for the groups was not analyzed as per the statistical plan.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>A p-value of &lt; 0.05 was considered statistically significant</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Muscle Oxygenation Recovery Time</title>
        <description>Change in muscle oxygenation after ischemia inducing occlusion for 4 minutes.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Subjects given Linagliptin
Linagliptin
MRI Scans: Phosphorus-31 MRI data was obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Subjects given sugar pill/placebo
Placebo
MRI Scans: Phosphorus-31 MRI data was obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Muscle Oxygenation Recovery Time</title>
          <description>Change in muscle oxygenation after ischemia inducing occlusion for 4 minutes.</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medial gastrocnemius</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="-6.2" upper_limit="13.9"/>
                    <measurement group_id="O2" value="7.1" lower_limit="-7.1" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral gastrocnemius</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="-6.6" upper_limit="11.3"/>
                    <measurement group_id="O2" value="2.2" lower_limit="-9.1" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Soleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-3.6" upper_limit="3.9"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-3.9" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tibialis anterior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.2" upper_limit="27.1"/>
                    <measurement group_id="O2" value="2.40" lower_limit="-6.6" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peroneus Longus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-4.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-2.0" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vascular Reactivity in the Micro- and Macro-circulation.</title>
        <description>Change in markers of macro- and microvascular function from the baseline visit to the post-treatment visit between the two groups.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Linagliptin treated group</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Subjects given sugar pill/placebo
Placebo
Microcirculation testing: The endothelial function of the micro-circulation was assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vascular Reactivity in the Micro- and Macro-circulation.</title>
          <description>Change in markers of macro- and microvascular function from the baseline visit to the post-treatment visit between the two groups.</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACh LDPI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="-9.5" upper_limit="25.4"/>
                    <measurement group_id="O2" value="-6.1" lower_limit="-15.3" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACh axon reflex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" lower_limit="-47.8" upper_limit="125.7"/>
                    <measurement group_id="O2" value="-7.4" lower_limit="-259.2" upper_limit="153.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flow mediated dilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="-0.58" upper_limit="1.58"/>
                    <measurement group_id="O2" value="0.36" lower_limit="-0.38" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitroglycerin mediated dilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="-0.78" upper_limit="1.62"/>
                    <measurement group_id="O2" value="0.11" lower_limit="-0.91" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in SDF1-α and Substance P</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Subjects given Linagliptin</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Subjects given sugar pill/placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in SDF1-α and Substance P</title>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SDF-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-100" upper_limit="28"/>
                    <measurement group_id="O2" value="11.1" lower_limit="-1.2" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Substance P</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="-69.7" upper_limit="348.0"/>
                    <measurement group_id="O2" value="42.2" lower_limit="-349.0" upper_limit="138.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Circulating Endothelial Progenitor Cell Phenotypes</title>
        <description>The measurements of the various EPC phenotypes were performed at the Beth Israel Deaconess Flow Cytometry Core Facility. Immunofluorescent cell staining was performed on peripheral blood with the use of the fluorescent conjugated antibodies. 1.000.000 events per sample were acquired using a FACS LSR II analyzer (Becton Dickinson, Franklin Lakes, NJ, USA) and the results were analyzed using the Beckman Coulter Kaluza analysis software (Beckman Coulter Inc., Brea, CA, USA).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Subjects given Linagliptin</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Subjects given sugar pill/placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Circulating Endothelial Progenitor Cell Phenotypes</title>
          <description>The measurements of the various EPC phenotypes were performed at the Beth Israel Deaconess Flow Cytometry Core Facility. Immunofluorescent cell staining was performed on peripheral blood with the use of the fluorescent conjugated antibodies. 1.000.000 events per sample were acquired using a FACS LSR II analyzer (Becton Dickinson, Franklin Lakes, NJ, USA) and the results were analyzed using the Beckman Coulter Kaluza analysis software (Beckman Coulter Inc., Brea, CA, USA).</description>
          <units>Events per million</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD133-KDR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="-20" upper_limit="111"/>
                    <measurement group_id="O2" value="1" lower_limit="-45" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KDR-CD34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-26" upper_limit="74"/>
                    <measurement group_id="O2" value="1" lower_limit="-15" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD133-CD34-KDR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-4" upper_limit="102"/>
                    <measurement group_id="O2" value="-3" lower_limit="-15" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>whole study period</desc>
      <group_list>
        <group group_id="E1">
          <title>Linagliptin</title>
          <description>Subjects given Linagliptin</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Subjects given sugar pill/placebo
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Decreased eGFR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg blisters</sub_title>
                <description>Blisters on legs</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Car accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cramping in the calf muscle during the graded exercise test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased creatinine and BUN, reduced GFR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Decreased CO2 concentration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lung water accumulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aristidis Veves</name_or_title>
      <organization>Beth Israel deaconess Medical Center</organization>
      <phone>617 632 7075</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

